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Background: In type 2 diabetes mellitus (T2DM) there is a progressive loss of β-cell function. 
One new approach yielding promising results is the use of the orally active dipeptidyl peptidase-4 
(DPP-4) inhibitors. However, every new compound for T2DM has to prove long-term safety 
especially on cardiovascular outcomes.
Objectives: Systematic review and meta-analysis of the effects of sitagliptin and vildagliptin 
therapy on main efﬁ  cacy parameters and safety.
Selection criteria, data collection, and analysis: Randomized controlled clinical studies 
of at least 12 weeks’ duration in T2DM.
Results: DPP-4 inhibitors versus placebo showed glycosylated hemoglobin A1c (A1c) improve-
ments of 0.7% versus placebo but not compared to monotherapy with other hypoglycemic agents 
(0.3% in favor of controls). The overall risk proﬁ  le of DPP-4 inhibitors was low, however a 
34% relative risk increase (95% conﬁ  dence interval 10% to 64%, P = 0.004) was noted for 
all-cause infection associated with sitagliptin use. No data on immune function, health-related 
quality of life and diabetic complications could be extracted.
Conclusions: DPP-4 inhibitors have some theoretical advantages over existing therapies with 
oral antidiabetic compounds but should currently be restricted to individual patients. Long-term 
data on cardiovascular outcomes and safety are needed before widespread use of these new 
agents.
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Introduction to management issues of T2DM
In type 2 diabetes mellitus (T2DM), the actions and secretion of insulin are impaired, 
as opposed to the absolute deﬁ  ciency of insulin that occurs with type 1 diabetes 
mellitus. Type 2 diabetes is characterized by two major pathophysiologic defects: 
(1) insulin resistance, which results in increased hepatic glucose production and 
decreased peripheral glucose disposal, and (2) impaired β-cell secretory function 
(Bloomgarden 2007). Insulin resistance is an impaired biological response to the 
effects of exogenous or endogenous insulin. Insulin resistance in the hepatic and 
peripheral tissues, particularly skeletal  muscle, leads to unrestrained hepatic glucose 
production and diminished insulin-stimulated peripheral glucose uptake and utiliza-
tion (DeFronzo et al 1992). Insulin secretion by the pancreatic β-cell is initially 
sufﬁ  cient to compensate for insulin resistance, thereby maintaining normal blood 
glucose levels. Hyperinsulinemia, which accompanies insulin resistance, can maintain 
sufﬁ  ciently normal glucose metabolism as long as pancreatic β-cell function remains 
normal. However, in patients who may develop type 2 diabetes, insulin secretion 
eventually fails, leading to hyperglycaemia and clinical diabetes (Kahn et al 2006). 
Individuals with type 2 diabetes may have few or no classic clinical symptoms of 
hyperglycemia (Ruige et al 1997). The difﬁ  culty in maintaining metabolic control, for 
example measured by glycosylated hemoglobin A1c (A1c) over time, may be related Vascular Health and Risk Management 2008:4(4) 754
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to several behavioral factors (for example difﬁ  culties with 
healthy eating, exercise, medication regimens) but primarily 
reﬂ  ects the underlying progressive decline in β-cell function 
(UKPDS-16 1995).
Type 2 diabetes has traditionally been treated in a step-
wise manner, starting with lifestyle modiﬁ  cations, exercise 
and later on pharmacotherapy with oral agents. Several 
classes of oral agents are available for clinical use. These 
mainly include insulin secretagogues, drugs that delay the 
absorption of carbohydrates from the gastrointestinal tract, 
and insulin sensitizers. Over time, many patients with type 
2 diabetes will require insulin therapy.
Diabetes has long been recognized as a strong, indepen-
dent risk factor for cardiovascular disease, a problem which 
accounts for approximately 70% of all mortality in people 
with diabetes (Laakso 1999; Ford 2005). Prospective studies 
show that compared with their nondiabetic counterparts, the 
relative risk of cardiovascular mortality for men with diabetes 
is two to three and for women with diabetes is three to four 
(Manson et al 1991; Stamler et al 1993). The increased car-
diovascular risk associated with diabetes is reﬂ  ected in the 
observation that middle-aged individuals with diabetes have 
mortality and morbidity risks that are similar to nondiabetic 
individuals who have already suffered a cardiovascular event 
(Haffner et al 1998).
Both epidemiological and prospective data have demon-
strated that treatment of hyperglycemia in T2DM is effective 
in reducing the risk of microvascular disease (for example 
diabetic retinopathy) but is less potent in reducing that of 
myocardial infarction, stroke, and peripheral vascular dis-
ease. Treatment of other cardiovascular risk factors, although 
by deﬁ  nition less prevalent than hyperglycemia, appears to 
be more effective in preventing macrovascular disease than 
treatment of hyperglycemia.
The United Kingdom Prospective Diabetes Study 
(UKPDS) tested mainly whether intensive glucose control 
with either a sulphonylurea or insulin inﬂ  uences the risk of 
micro- and macrovascular complications compared with 
conventional treatment (UKPDS-33 1998). The 10-year 
results of the UKPDS evaluated drug treatment in nonobese 
and obese participants with newly diagnosed type 2 diabetes 
who were referred to hospital clinics. Over 10 years, A1c 
was 7.0% in the intensive group compared with 7.9% in the 
conventional group. Less than half of US adults with type 2 
diabetes reach an A1c level of less than 7% despite various 
available therapies (Resnick et al 2006).
The UKPDS had a factorial design meaning that another 
study investigating intensive versus regular blood pressure 
control (HDS 1993; UKPDS-38 1998) was imbedded in 
the main study. Intensive versus conventional glucose 
control did not result in a statistically signiﬁ  cant differ-
ence in diabetes related mortality or macrovascular disease 
endpoints but reduced the relative risk in the ‘any diabetes 
related aggregate endpoint’ (Freemantle et al 2003). In the 
UKPDS, the number needed to treat (NNT) to prevent one 
patient developing any of the single endpoints over 10 years 
was 20 (95% conﬁ  dence interval [CI] 10 to 500) patients 
(UKPDS-33 1998). In contrast to these results, publication of 
the UKPDS-34 (1998), which focused on obese patients with 
newly diagnosed type 2 diabetes, found several clinically 
important differences in macrovascular disease endpoints 
with 10 years of treatment with metformin. In particular, the 
absolute risk reduction for the aggregate endpoints was more 
than 10% and for overall mortality was 7%, giving NNTs 
of 10 and 14, respectively, over 10 years (McCormack and 
Greenhalgh 2000).
The UKPDS was criticized on several grounds especially 
emphasizing hidden biases in interpreting the results of this 
randomized controlled trial (Ewart 2001; McCormack and 
Greenhalgh 2000; Nathan 1998). Moreover, the UKPDS-38, 
investigating tight versus less tight blood pressure control 
with the use of an angiotensin-converting enzyme inhibitor 
captopril or a β-blocker atenolol as main treatment, showed 
relative risk reductions (in the group assigned to tight control 
compared with that assigned to less tight control) of 24% 
in diabetes related endpoints, 32% in deaths related to dia-
betes, 44% in strokes and 37% in microvascular endpoints 
(UKPDS-38 1998).
As type 2 diabetes develops, there is a progressive loss 
of β-cell function and intensiﬁ  cation of therapy is often 
required over time. Currently available therapies for T2DM 
have various limitations and may also be associated with an 
increased risk of hypoglycemia (eg, sulphonylureas, insulin), 
weight gain (eg, sulphonylureas, thiazolidinediones, insulin), 
and gastrointestinal side effects (eg, metformin) as well as 
edema and heart failure (eg, thiazolidinediones).
Research into the pathophysiology of diabetes has 
demonstrated that a complex interplay of hormonal and 
neural stimuli, not just insulin and glucagon, are involved 
in the regulation of glucometabolic control (Drucker and 
Nauck 2006).
One new approach yielding promising results is the use 
of agents that are based on gut incretin hormones, which 
appear to be malfunctioning in type 2 diabetes mellitus and 
have important effects on insulin and glucagon biology as 
well as central nervous system effects on appetite. These Vascular Health and Risk Management 2008:4(4) 755
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new treatments include glucose-dependent insulinotropic 
peptide (GIP) and glucagon-like peptide-1 (GLP-1) 
(“incretin”) mimetics as well as dipeptidyl peptidase-4 
(DPP-4) inhibitors. In April 2005, the US Food and Drug 
Administration (FDA) approved the ﬁ  rst incretin mimetic, 
exenatide, a GLP-1 receptor analogue which is resistant 
to DPP-4 degradation. Because GLP-1 analogues require 
injection, much effort has been allocated to create an oral 
agent targeting the incretin pathway.
The other approach for GLP-1 based therapy is to inhibit 
the enzyme activity of DPP-4. Several DPP-4 inhibitors are 
orally active and potentiate and prolong the effects of the 
incretins. Currently, most experience exists for sitagliptin 
and vildagliptin, which both have a long duration of action, 
allowing once daily administration.
Depending on the beneﬁ  t-risk ratio it might happen that 
DPP-4 inhibitors will be a ﬁ  rst-line treatment strategy of 
the early stages of type 2 diabetes in the future, particularly 
in combination with metformin. On the other hand, any 
new compound in the treatment of type 2 diabetes mellitus, 
has to prove long-term safety and efﬁ  cacy. Apart from 
surrogate outcomes like reductions in fasting plasma 
glucose or A1c, patient-important endpoints such as effects 
on cardiovascular disease should be the prime target 
of diabetes research (Cleland and Atkin 2007; Montori 
et al 2007).
The focus of this review is on clinical studies of at least 12 
weeks’ duration investigating the beneﬁ  t-risk ratio of DPP-4 
inhibitor therapy in type 2 diabetic people.
Mode of action, pharmacology, 
and pharmacokinetic/-dynamic 
proﬁ  le of DPP-4 inhibitors
The two incretin hormones
An incretin hormone is a gut hormone that is released into 
the blood after meal ingestion and stimulates insulin secre-
tion in a glucose-dependent manner. This accounts for the 
marked prandial insulin response, which prevents prandial 
hyperglycemia. The incretin concept was established in the 
1960s and it was later demonstrated that, for a given rise in 
plasma glucose concentration, the increase in plasma insulin 
is approximately threefold greater when glucose is adminis-
tered orally compared with intravenously (Kreymann et al 
1987; Creutzfeld 2005).
The most important incretin hormones are the glucose-
dependent insulinotropic peptide (GIP) and GLP-1 (Effendic 
and Portwood 2004). GLP-1 is a 30 amino acid polypeptide, 
which is produced by the intestinal L-cells localized mainly 
in the distal portion of the small intestine and in the large 
intestine. GIP is a 42 amino acid polypeptide, which origi-
nates from the intestinal K-cells localized mainly in the 
duodenum. However, L-cells are also found in the duode-
num and endocrine cells also co-express GLP-1 and GIP 
(Mortensen et al 2003).
GIP and GLP-1 are thought to be responsible for the 
full incretin effect. Patients with type 2 diabetes exhibit an 
attenuated insulinotropic action of GIP but not GLP-1 and 
a signiﬁ  cant reduction in meal-stimulated levels of GLP-1 
(Nauck et al 1993; Toft-Nielsen et al 2001). Because GLP-1 
effects remain relatively intact in type 2 diabetic patients, 
most pharmaceutical efforts try to potentiate incretin action 
through GLP-1 mimetics or agonists.
As GIP and GLP-1 together are responsible for the 
incretin effect in healthy people, the incretin defect in 
T2DM could theoretically arise because of impaired 
secretion, accelerated metabolism, defective function 
of the incretin hormones or their associated receptors, 
increased activity of DPP-4 (Mannucci et al 2005) as 
well as through additional mechanisms, eg, action of 
neuropeptides (Nauck and El-Ouaghlidi 2005). Therefore, 
several mechanisms may explain the reduced incretin 
action in type 2 diabetes.
Plasma concentrations of both incretins increase within 5 
to 15 min after meal ingestion: GLP-1 is primarily released 
by the ingestion of carbohydrate, fat and protein, whereas 
GIP is mainly liberated by the ingestion of carbohydrate and 
fat (Deacon 2005). Up to two-thirds of the insulin normally 
secreted in relation to a meal are thought to be a result of the 
effects of these hormones.
The actions of both incretins depend on glucose concen-
tration, and their function ceases when serum glucose level is 
less than 55 mg/dL (3.1 mmol/L) (Drucker et al 1987). After 
their release, the two hormones circulate in the blood and 
reach their target cells to activate their receptors.
The interaction of the incretins with their G-protein 
coupled receptor, which is expressed on pancreatic 
β-cells, is the increased formation of cyclic adenosine 
30, 50-monophosphate (cAMP), which activates protein 
kinase A (PKA). This closes adenosine triphosphate (ATP)-
regulated potassium channels in the presence of elevated 
glucose levels (Gromada et al 1998; Light et al 2002) and 
inhibits voltage-dependent potassium channels (MacDonald 
et al 2002) leading to an increase in intracellular calcium-
enhancing exocytosis of insulin-containing granules 
(Gromada et al 1998).Vascular Health and Risk Management 2008:4(4) 756
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Both GIP and GLP-1 receptors are expressed in 
various tissues. GLP-1 receptors are found in pancreatic 
islets, vagal nerves, stomach, lung, kidney, and the brain, 
whereas GIP receptors are expressed in pancreatic islets, 
the brain and adipose tissue (Mayo et al 2003; Wideman 
and Kieffer 2004).
Besides the direct stimulation of islet β-cells, GLP-1 
may also promote insulin secretion indirectly through the 
activation of sensory nerves (Ahrén 2004) suggesting an 
important neural contribution to GLP-1-induced insulin 
secretion, which could explain the rapid insulinotropic action 
after meal ingestion (Holst and Deacon 2005).
Direct effects of GLP-1 on β-cell growth and survival 
could be demonstrated in animal models, with GLP-1 stimu-
lated proliferation and differentiation of new β-cells together 
with an inhibition of β-cell apoptosis (Xu et al 1999; Perfetti 
et al 2000; Stoffers et al 2000; Farilla et al 2003). These 
effects lead to an increased β-cell mass.
Moreover, GLP-1 suppresses glucagon secretion in a 
glucose-dependent manner and is not thought to impair 
the glucagon counter-regulatory response to hypoglycemia 
(Nauck et al 2002). GLP-1 inhibits gastric emptying and 
food ingestion, thus reducing meal-associated increases in 
glycemic excursions, and may enhance glucose disposal and 
insulin sensitivity (Drucker and Nauck 2006).
Mechanism of action of DPP-4 
inhibition
GLP-1 itself is unpromising as maintenance therapy of 
diabetes, because the hormone is rapidly inactivated by the 
action of DPP-4 (Deacon 2004). Both GLP-1 and GIP are 
inactivated by DPP-4 resulting in a short half-life, which is 
1 to 2 min for GLP-1 and 5 to 7 min for GIP (Deacon 2005). 
Almost 50% of this degradation occurs at the intestinal 
capillaries close to the site of GLP-1 and GIP release. GIP-
inhibition is probably less important for the antidiabetic 
actions of DPP-4 inhibitors, since GIP seems to have lost 
much of its insulinotropic action in type 2 diabetes (Meier and 
Nauck 2004). As a result of DPP-4 activity, intact, biologically 
active GLP-1 represents only 10% to 20% of total plasma 
GLP-1 (Deacon et al 1995).
The strategy of inhibiting DPP-4 is to prevent the inac-
tivation of GLP-1 and therefore to enhance and prolong 
the effects of the endogenously released incretin hormone. 
It could be demonstrated that DPP-4 inhibition increases 
circulating levels of GLP-1 in experimental animals and 
that the insulinotropic action of exogenously administered 
GLP-1 is intensiﬁ  ed by DPP-4 inhibition (Holst and Deacon 
1998). DPP-4 inhibition increases not only prandial but 
also fasting levels of active GLP-1 and results in an overall 
increase in GLP-1 levels with maintenance of circadian 
rhythm throughout the day.
Through preventing the rapid degradation of incretin 
hormones, DPP-4 inhibitors result in postprandial increases in 
levels of biologically active intact GLP-1 and reduce glucose 
production from the liver by inhibition of glucagon from the 
α-cells of the pancreas and increasing insulin production. Three 
DPP-4 inhibitors are currently in late-stage development: 
vildagliptin, sitagliptin and saxagliptin. Sitagliptin received 
FDA approval as well as European Medicines Agency 
(EMEA) marketing authorization. Vildagliptin was also 
granted EMEA marketing authorization.
DPP-4 acts by cleavage of the two N-terminal amino acids 
of bioactive peptides, provided that the second amino acid is 
alanine or proline. Since the second N-terminal amino acid in 
GLP-1 is alanine, GLP-1 is cleaved to a truncated form 
(Deacon 2004) which is largely inactive; therefore the 
cleavage of GLP-1 by DPP-4 is an inactivation process. The 
cleavage is rapid, which is the reason why native GLP-1 has 
a short half-life (less than 2 min).
DPP-4, also known as the lymphocyte cell surface marker 
CD 26, is a ubiquitous complex enzyme that exists as a mem-
brane-spanning cell-surface aminopeptidase that transmits 
intracellular signals via a short intracellular tail and a second 
smaller soluble form circulating in the plasma (Lambeir et al 
2003). It is widely expressed in many tissues, such as liver, 
lung, kidney, intestine, lymphocytes, capillary endothelium 
and T-cells, B-cells and natural killer cells (Mentlein 1999; 
De Meester et al 2000).
As a T-cell costimulator, DPP-4 is of importance in 
the immune system. The extracellular domain of DPP-4 
can also be cleaved from its membrane-anchored form 
and circulate in plasma, where it retains its full enzymatic 
activity. DPP-4 preferentially cleaves peptides with a proline 
or alanine residue in the second aminoterminal position. 
Many gastrointestinal hormones, neuropeptides, cytokines, 
and chemokines as well as the endogenous physiological 
compounds GIP and GLP-1 are substrates for DPP-4 
(De Meester et al 2003).
DPP-4 is a member of a complex gene family includ-
ing ﬁ  broblast activation protein, DPP-6, DPP-8, DPP-9, 
quiescent cell proline dipeptidase, and DPP-4β (Busek et al 
2004). This mandates careful evaluation of the selectivity 
of any agent used to inhibit DPP-4 activity and long-term 
safety studies (Lancas et al 2005). At least two human 
dipeptidyl-peptidases, DPP-8 and DPP-9, whose functions Vascular Health and Risk Management 2008:4(4) 757
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are still unknown, are structurally closely related to DPP-4. 
Acute toxicity in animal models was reported for at least 
one compound with strong DPP-8/DPP-9 inhibitory potency 
(Lancas et al 2005). In patients suffering from rheumatoid 
arthritis DPP-4 activity was inversely correlated with the 
severity of the disease (Busso et al 2005), indicating a role 
for DPP-4 in the control of immune regulation.
It is currently unknown whether ‘selective’ DPP-4 
inhibitors used for the treatment of type 2 diabetes play a role 
in the control of immune function, transplantation biology or 
cancer cell growth (Dang and Morimoto 2002).
Currently, all data obtained using ‘nonselective’ and 
‘selective’ DPP inhibitors need to be interpreted with cau-
tion. It is not known whether in vivo DPP-8 and DPP-9 
are inhibited on administration of therapeutic doses of the 
DPP-4 inhibitors. However, to date no in vivo effects have 
been reported that point to a pharmacological impact of the 
inhibition of other peptidases.
Numerous endocrine peptides, chemokines, and 
neuropeptides such as bradykinin, endomorphin-2, growth 
hormone-releasing hormone, interleukin-2 and -1β, 
prolactin, neuropeptide Y and substance P are putative 
but questionable physiological DPP-4 substrates (Drucker 
2007). Levels of tissue DPP-4 are reduced in nasal tissue 
of people with chronic rhinosinusitis and DPP-4 inhibition 
seems to aggravate nasopharyngitis as could be observed in 
clinical studies. Therefore, it seems to be highly important 
to monitor DPP-4-treated patients for the development of 
inﬂ  ammatory conditions, such as angioedema, rhinitis, 
and urticaria.
DPP4 also regulates migration of human cord blood 
CD34+ progenitor cells and the homing and engraftment of 
hematopoetic stem cells.
Pharmacokinetic/-dynamic proﬁ  le
The current DPP-4 inhibitors display slow, tight-binding 
inhibition kinetics and are reversible competitive inhibitors 
of DPP-4 (Henness and Keam 2006; He et al 2007; Lyseng-
Williamson 2007). Sitagliptin and vildagliptin have been 
explored in detail, both possess pharmacokinetic properties 
that support a once-daily dosing regimen. Clinically impor-
tant pharmacokinetic/-dynamic parameters are summarized 
in Table 1.
Sitagliptin and vildagliptin are both orally active, rapidly 
absorbed, and mainly excreted by the kidneys. Whereas 
hepatic insufﬁ  ciency does not seem to alter pharmacoki-
netics of these compounds, dose adjustments are required 
in patients with renal impairment, at least for sitagliptin 
(Bergman et al 2007). Vildagliptin is not recommended 
for patients with severe liver problems (EMEA 2007b). It 
is recommended that renal function is assessed prior to the 
start of sitagliptin treatment. Studies in patients with renal 
insufﬁ  ciency have not been reported to date on vildagliptin 
therapy. Both DPP-4 inhibitors should not be used for 
patients with moderate or severe kidney problems (EMEA 
2007a, 2007b).
DPP-4 activity is inhibited by almost 100% at 15 to 30 
min after oral ingestion, and more than 80% inhibition lasts 
for more than 16 hours due to the initial phase of rapid bind-
ing followed by a slow phase of very tight binding kinetics 
(Ahrén et al 2004a).
The pharmacokinetics of vildagliptin and sitagliptin do 
not seem to be affected by age, gender, ethnicity, or body 
mass index. Co-administration of DPP-4 inhibitors with 
several other antidiabetic agents and other drugs including 
digoxin, simvastatin, and warfarin has so far not uncovered 
any relevant drug interactions.
The recommended dosage of sitagliptin is 100 mg orally 
once daily, either as monotherapy or in antidiabetic combina-
tion therapy, taken with or without food (EMEA 2007a). The 
recommended dose of vildagliptin is 100 mg when used with 
metformin or a thiazolidinedione or 50 mg in combination 
with a sulphonylurea (EMEA 2007b).
Efﬁ  cacy studies
Search strategy
We identified studies by a systematic literature search 
of MEDLINE, EMBASE, and the Cochrane Library for 
randomized controlled clinical trials, systematic reviews, 
meta-analyses and health-technology assessment reports 
Table 1 Clinically important pharmacokinetic/-dynamic parameters 
of current DPP-4 inhibitors
 Sitagliptin  Vildagliptin
Selectivity for DPP-4 over DPP-8/9   2600 32–250
[-fold]
Absolute bioavailability [%]  87  85
Time to reach maximum plasma   2  1–2
concentration, Tmax [hr]
Volume of distribution [L]  198  70.5
Plasma protein binding [%]  38  9
Terminal half life, T1/2 [hr]  11.0  1.7a
Renal clearance [L/hr]  21  13
Elimination in urine [%]  87  85
Recommended dosage [mg/day]  100  100
Notes: a100 mg once daily (2.5 hrs with 100 mg twice daily).
Abbreviations: DPP-4, dipeptidyl peptidase-4.Vascular Health and Risk Management 2008:4(4) 758
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of DPP-4 inhibitor therapy in adults with type 2 diabetes 
mellitus. Search terms included “sitagliptin”, “vildagliptin”, 
“saxagliptin”, “gliptin”, “incretin”, “dipeptidyl peptidase”, 
“DPP”, “LAF237”, and “MK-0431”. The title and abstract of 
studies identiﬁ  ed in the search were scanned by two reviewers 
to exclude any hits that clearly were irrelevant. The full text 
of the remaining articles was read to determine whether it 
contained information on the topic of interest. The reference 
lists of the remaining articles as well as all reviews on the 
topic were also reviewed for additional pertinent studies. 
Abstracts of research presented at related conferences were 
also searched.
We followed the QUOROM (quality of reporting of 
meta-analyses) guidelines (Moher et al 1999) and the 
methodology recommended by the Cochrane Handbook 
for Systematic Reviews of Interventions (Higgins and 
Green 2006) for reporting our meta-analysis methods and 
results.
Selection criteria
We included studies of at least 12 weeks’ duration because 
such studies would give an adequate assessment of change in 
glycemic efﬁ  cacy, as glycosylated hemoglobin A1c reﬂ  ects 
glycemia during the previous three months (Goldstein 
et al 2004). When there were multiple publications or 
companion papers from the same population we tried to 
maximize yield of information by simultaneous evaluation 
of all relevant study data. Any discrepancies were resolved 
by consensus between two independent reviewers or with 
the help of a third author via referencing the original 
article.
Data extraction and risk of bias 
assessment
Two reviewers abstracted data independently. Participant 
baseline characteristics of the included studies were 
extracted. We obtained data for glycemic efﬁ  cacy from 
change from baseline to study endpoint in A1c. Data on 
change in body weight were also extracted. To evaluate 
safety, we extracted data on hypoglycemic episodes and all 
reported adverse events. Description of allocation conceal-
ment, intention- to-treat analysis, and attrition rates were 
mainly used to evaluate risk of bias.
Data synthesis and analysis
The primary measure for glycemic efﬁ  cacy was the treatment 
group difference in A1c change from baseline to study 
endpoint. For safety, we analyzed the number of participants 
reporting adverse events. For continuous variables (A1c, 
body weight), we calculated weighted mean differences and 
95% conﬁ  dence intervals (CIs) for change from baseline in 
DPP-4 inhibitors versus control (placebo or hypoglycemic 
agent) groups. For dichotomous variables (adverse events), 
we calculated the odds ratios and 95% CIs for DPP-4 
inhibitors versus control. If data from more than two trials 
were available, we combined data from trials and explored 
heterogeneity between comparable trials with prespeciﬁ  ed 
subgroup analyses by type of comparator group (placebo vs 
hypoglycemic agent) and duration of intervention (12 versus 
longer than 12 weeks), for each compound separately. For 
sitagliptin and vildagliptin mainly data on the recommended 
100 mg/day dosage were used.
Meta-analyses were performed by means of a random-
effects model. Many studies reported differences in the 
mean changes and the corresponding 95% CIs (or standard 
errors) between comparison groups. Standard errors were 
converted to standard deviations by multiplying standard 
errors of means by the square-root of the sample size: 
SD = SE × √N (Higgins and Green 2006). Conﬁ  dence 
intervals for mean changes within treatment groups were 
also converted to standard deviations. If the sample size was 
large, the standard deviation for each group was obtained 
by dividing the length of the 95% conﬁ  dence interval by 
3.92, and then multiplied by the square root of the sample 
size: SD = √N × ((upper CI limit – lower CI limit)/3.92) 
(Higgins and Green 2006).
In the event of substantial clinical or methodological or 
statistical heterogeneity, study results were not combined 
by means of meta-analysis. Heterogeneity was identiﬁ  ed 
by visual inspection of the forest plots, by using a standard 
χ2-test and a signiﬁ  cance level of α = 0.1, in view of the low 
power of such tests. Heterogeneity was speciﬁ  cally examined 
with I2 (Higgins and Thompson 2002), where I2 values of 
50% and more indicate a substantial level of heterogeneity 
(Higgins et al 2003). When heterogeneity was found, we 
attempted to determine potential reasons for it by examining 
individual study characteristics and those of subgroups of the 
main body of evidence.
Search results and study characteristics
The initial search revealed 886 abstracts, out of these 85 
full publications were evaluated. After extraction of reviews 
and exclusion of studies (n = 13, main reason was duration 
of trial less than 12 weeks) 22 publications remained, 12 
reported on vildagliptin therapy (Ahrén et al 2004b; Ristic 
et al 2005; Mimori et al 2006; Pratley et al 2006; Bosi et al Vascular Health and Risk Management 2008:4(4) 759
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2007; Dejager et al 2007; Fonseca et al 2007; Garber et al 
2007; Pi-Sunyer et al 2007; Rosenstock et al 2007a, 2007b; 
Schweizer et al 2007) in type 2 diabetes and 10 on sitagliptin 
treatment (Aschner et al 2006; Charbonnel et al 2006; 
Nonaka et al 2006; Raz et al 2006; Rosenstock et al 2006; 
Goldstein et al 2007; Hanefeld et al 2007; Hermansen et al 
2007; Nauck et al 2007; Scott et al 2007).
Most studies were performed in a multicenter design, 
mainly in North America and Europe, with participating 
countries ranging from 1 to 34 (mean 16) for sitagliptin and 
1 to 11 (mean 5) for vildagliptin, respectively.
The main baseline characteristics for the 22 included 
trials are summarized in Table 2.
The median duration of sitagliptin/vildagliptin trials was 
24 weeks. There was one study in each DPP-4 inhibitor class 
which investigated the primary randomized patient group 
after one year of treatment.
Six (five) study arms directly compared sitagliptin 
(vildagliptin) with placebo, two (three) with another 
hypoglycemic agent and five (five) contrasted various 
combination therapies.
Gender ratio was roughly balanced between the 
sitagliptin/vildagliptin intervention/control groups and also 
comparing the two agents with each other. Participants 
were mostly white, obese, around 55 years of age with a 
duration of diabetes between three to ﬁ  ve years. A large 
proportion across all trials consisted of participants who 
were treated by diet and/or exercise only. Baseline A1c was 
slightly worse in the sitagliptin/vildagliptin control groups 
(+0.5%/+0.2%, respectively). No publication revealed data 
on co-morbidities.
Risk of bias
All studies included a control group in a double-blind design, 
besides one vildagliptin trial involving insulin, which had 
an open-label design (Fonseca et al 2007). One sitagliptin 
(Nauck et al 2007) and two vildagliptin studies (Rosenstock 
et al 2007a; Schweizer et al 2007) tested for noninferiority. 
One vildagliptin trial described power calculation (Schweizer 
et al 2007).
Key quality criteria of risk of bias reduction are outlined 
in Table 3.
No study clearly described method of randomization or 
concealment of allocation. Most publications mentioned 
intention-to-treat analysis with last-observation carried 
forward for missing primary efﬁ  cacy endpoints.
The total number of randomized type 2 diabetes 
participants in the included sitagliptin/vildagliptin studies 
was 6028/5239. Mean attrition rates were rather high, ranging 
from 16% to 17%, with high withdrawal rates in the placebo 
groups due to loss of glycemic control. All studies were 
funded by pharmaceutical companies with a considerable 
number of individuals from the industries named as authors 
in the publications.
Table 3 Key indicators for reduction of risk of bias in randomized 
controlled trials of DPP-4 inhibitor therapy
 Sitagliptin  Vildagliptin
Method of randomization   0/12  0/12
described [n studies]
Concealment of allocation   0/12  0/12
described [n studies]
Intention-to-treat analysis   9/10  11/12
mentioned [n studies]
Missing data: imputation   9/10  11/12
method used [n studies]
No. of randomized patients   3691/2337  3604/1635
[intervention/control]
Mean discontinuation rate [%]  15.8  17.2
Abbreviations: DPP = 4, dipeptidyl peptidase-4.
Table 2 Main baseline characteristics (mean values across all study arms) of randomized controlled trials of DPP-4 inhibitors
 Sitagliptin    Vildagliptin
 Interventiona Controlb Interventiona Controlb
Female sex [%]  49.2  47.7  45.9  45.2
Age [yrs]  55.0  54.2  54.4  54.2
Ethnic group, white participants [%]  68.8  59.1  67.5  67.2
Duration of disease [yrs]  4.5  4.7  3.3  4.4
Body mass index [kg/m2] 31.5 31.7  31.4  31.8
Pharmaco-naïve patientsc [%]  39.9  45.4  d  d
HbA1c [%]  8.0  8.5  8.2  8.4
Notes: aintervention indicates active sitagliptin or vildagliptin treatment; bcontrol denotes placebo or hypoglycemic comparator; ctype 2 diabetic patients on exercise and/or 
diet only; dpatients on no antidiabetic drugs was an inclusion criterion in 7/12 studies.
Abbreviations: DPP-4, dipeptidyl peptidase-4; HbA1c, hemoglobin A1c.Vascular Health and Risk Management 2008:4(4) 760
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Outcomes
Unfortunately, so far no study investigated patient-oriented 
parameters like diabetic complications, health-related quality 
of life and treatment satisfaction.
All trials evaluated A1c change from baseline to 
(imputed) endpoint as the primary efﬁ  cacy parameter. Sec-
ondary outcomes (speciﬁ  ed as such in 16/22 publications) 
varied, but mostly included fasting plasma glucose, fasting 
lipids, body weight and investigations of β-cell function 
and insulin sensitivity. Safety evaluation encompassed 
adverse experiences including hypoglycemic episodes and 
pre-speciﬁ  ed gastro-intestinal events such as abdominal 
pain, nausea, vomiting and diarrhea. Furthermore, physical 
examinations, evaluation of vital signs, electrocardiograms 
and safety laboratory assessments were mentioned in all 
publications.
Figure 1.1 shows the effects of vildagliptin treatment 
on A1c mean changes in the course of the study. The ﬁ  rst 
panel provides an overview of all study arms for illustrating 
purposes only. Compared to placebo, vildagliptin resulted 
in a signiﬁ  cant reduction of A1c but with a substantial 
amount of heterogeneity (I2 = 93.2%). Elimination of the 
study by Mimori and colleagues (2006), investigating 
Japanese patients only, resulted in a sizable reduction 
of heterogeneity (I2 = 25.4%) with a more stable pooled 
effect size of −0.6% A1c reduction (95% CI −0.8 to −0.4, 
P  0.00001) in favor of vildagliptin. Contrasted to another 
single hypoglycemic agent, vildagliptin demonstrated 
less lowering of A1c (mean difference 0.3%, 95% CI 0.1 
to 0.5, P = 0.0002), non-inferiority to metformin was 
not established. When combined with other antidiabetic 
compounds, vildagliptin lead to an additional lowering 
of A1c (−0.7%, 95% CI −0.9 to −0.4, P  0.00001). The 
effects of vildagliptin on metabolic control did not decrease 
if the effects of 12 weeks’ versus 24 weeks’ treatment in 
comparison to placebo were analyzed.
Figure 2.1.1 reveals the effects of sitagliptin treatment on 
A1c mean changes. The ﬁ  rst panel provides an overview of 
all study arms for illustrating purposes only. Compared with 
placebo, sitagliptin resulted in a signiﬁ  cant reduction of A1c 
(−0.7%, 95% CI −0.9% to −0.6%, P  0.00001). Contrasted 
to another single hypoglycemic agent, sitagliptin was infe-
rior (mean difference 0.3%, 95% CI 0.1 to 0.6, P = 0.007). 
Sitagliptin combination therapy lead to additional lowering 
of A1c but heterogeneity was substantial. The effects of 
sitagliptin on metabolic control did also not diminish if the 
A1c of 12 weeks’ versus 24 weeks’ treatment and against 
placebo were compared.
Safety and tolerability
Severe hypoglycemia as deﬁ  ned by requiring third party 
assistance was not reported in patients taking DPP-4 
inhibitors. There were no statistically signiﬁ  cant differences 
(data not shown) in hypoglycemic episodes between 
sitagliptin/vildagliptin and comparator groups. Also, risk of 
gastrointestinal adverse effects was comparable to placebo. 
Headache was reported more often with DPP-4 inhibitors, 
especially following vildagliptin therapy (data not shown). 
Overall, sitagliptin and vildagliptin were well tolerated.
Figures 1.2.1 and 2.2.1 display attrition rates due to 
adverse events, number of serious adverse events, and all-
cause infections.
Withdrawals due to adverse effects of DPP-4 inhibitor 
treatment were not signiﬁ  cantly raised in comparison to 
control groups (odds ratio for vildagliptin 0.85, 95% CI 
0.58 to 1.25; odds ratio for sitagliptin 0.92, 95% CI 0,69 
to 1.24).
Also, serious adverse events were not observed more 
often following DPP-4 inhibition (odds ratio for vildagliptin 
0.86, 95% CI 0.51 to 1.46; odds ratio for sitagliptin 1.07, 
95% CI 0.82 to 1.40).
However, after combining studies with available 
data, there was an increased risk of all-cause infections 
(nasopharyngitis, sinusitis, upper respiratory tract infec-
tion, urinary tract infection, viral infection) for sitagliptin 
(odds ratio 1.34, 95% CI 1.10 to 1.64, P = 0.004), but not 
for vildagliptin.
Figures 1.3.1 and 2.3.1 show the effects of DPP-4 inhibi-
tion on body weight. The ﬁ  rst panel provides an overview of 
all study arms for illustrating purposes only.
Fifteen studies provided data on weight changes. Com-
pared to placebo, a small increase in weight was noted 
after DPP-4 inhibitor treatment (vildagliptin +0.8 kg, 95% 
CI 0.2 to 1.3, P = 0.009; sitagliptin +0.7 kg, 95% CI 0.2 to 
1.2, P = 0.008). Comparison of DPP-4 inhibitors versus all 
hypoglycemic agents did not indicate signiﬁ  cant differences 
between comparators for pooled effect sizes. Taking into 
account different classes of antidiabetic agents, a favorable 
weight proﬁ  le was noted when vildagliptin was compared 
to pioglitazone as well as after sitagliptin/metformin versus 
glipizide/metformin combination therapy.
Conclusions and place in therapy
Overall, the magnitude of the A1c improvements with 
DPP-4 inhibitors versus placebo was 0.7% but could not 
be replicated in direct comparison to monotherapy with 
other hypoglycemic agents (0.3% A1c reduction in favor of Vascular Health and Risk Management 2008:4(4) 761
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Figure 1.1 Mean HbA1c changes [%] from baseline to (imputed) endpoint in vildagliptin randomised controlled trials. Weighted mean differences by means of random-effects 
model (inverse varicance (IV) method) showing 95% conﬁ  dence intervals (CI) for single studies and pooled effect sizes. I2 describes the percentage of total variation across 
studies due to heterogeneity.
Abbreviations: HbA1c, hemoglobin A1c.
difference differenceVascular Health and Risk Management 2008:4(4) 762
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controls). Compared with placebo, a small increase in weight 
was noted (0.7 to 0.8 kg). The overall risk proﬁ  le was low, 
however an increased relative risk of 34% for all-cause infec-
tions after sitagliptin treatment was observed. Although, the 
risk of increased infection appears small, its consequences 
when translated into clinical practice with millions of type 2 
diabetic patients treated could be considerable (Amori et al 
2007).
The low rate of hypoglycemic events seen across studies 
conﬁ  rms the glucose-dependent actions of the DPP-4 inhibi-
tors (Drucker and Nauck 2006). However, hypoglycemia is 
still possible, especially in combination therapies. All these 
Figure 1.2 Attrition rates due to adverse events, number of serious adverse events and all-cause infections in vildagliptin randomized controlled trials. Odds ratios by means 
of random-effects model (Mantel-Haenszel (M-H) method) showing 95% conﬁ  dence intervals (CI) for single studies and pooled effect sizes. I2 describes the percentage of 
total variation across studies due to heterogeneity.
ratio ratioVascular Health and Risk Management 2008:4(4) 763
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results have to be interpreted with caution due to the relatively 
high risk of bias with high attrition rates and poor reporting 
of key quality indicators.
Traditional treatments for type 2 diabetes do not seem to 
address the progressive decline in β-cell function and patients 
continue to advance in their disease state. DPP-4 inhibitors 
could theoretically preserve and even reverse the progressive 
loss of insulin secretory capacity, although long-term studies 
in type 2 diabetic patients will be required to demonstrate 
this change.
Currently, there are no head-to-head studies comparing 
sitagliptin and vildagliptin, and caution must therefore be 
exercised in judging relative efﬁ  cacy. Theoretically, DPP-4 
inhibition seems to have the strongest potential in early 
stages of type 2 diabetes because of the impaired GLP-1 
secretion in type 2 diabetes, together with both poor insulin 
secretion and sensitivity as well as partial insensitivity to 
GLP-1.
However, there is a considerable risk of potential adverse 
effects of DPP-4 inhibitors, especially on the immune system. 
It is disturbing to note that in all our included published 
randomized controlled trials of sitagliptin/vildagliptin only 
routine laboratory safety measurements were reported. Why 
were elaborated laboratory measurements not performed or 
reported? The best chance to do so was under well-controlled 
early stage efﬁ  cacy studies. Moreover, due to the important 
association of type 2 diabetes with cardiovascular disease 
any new antihypoglycemic agent for type 2 diabetes should 
be investigated for its effects on cardiovascular risk and 
outcomes.
As a consequence of recently discovered complications 
with another antidiabetic compound (Rosen 2007), it was 
discussed that regulatory authorities should change their 
way of approval of antidiabetic drugs which still focuses on 
glucose-lowering potencies of new medications (Solomon 
and Winkelmayer 2007) instead on patient-important 
outcomes (Montori et al 2007).
Summarizing our ﬁ  ndings, DPP-4 inhibitors present 
a desirable additional choice and possible alternative 
treatment option to presently available antidiabetic agents 
Figure 1.3 Mean body weight changes [kg] in vildagliptin randomised controlled trials. Weighted mean differences by means of random-effects model (inverse varicance (IV) 
method) showing 95% conﬁ  dence intervals (CI) for single studies and pooled effect sizes. I2 describes the percentage of total variation across studies due to heterogeneity.
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Figure 2.1 Mean HbA1c changes [%] from baseline to (imputed) endpoint in sitagliptin randomised controlled trials. Weighted mean differences by means of random-effects 
model (inverse varicance (IV) method) showing 95% conﬁ  dence intervals (CI) for single studies and pooled effect sizes. I2 describes the percentage of total variation across 
studies due to heterogeneity.
Abbreviations: HbA1c, hemoglobin A1c.
difference differenceVascular Health and Risk Management 2008:4(4) 765
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ratio ratio
Figure 2.2 Attrition rates due to adverse events, number of serious adverse events and all-cause infections in sitagliptin randomised controlled trials. Odds ratios by means 
of random-effects model (Mantel-Haenszel (M-H) method) showing 95% conﬁ  dence intervals (CI) for single studies and pooled effect sizes. I2 describes the percentage of 
total variation across studies due to heterogeneity.Vascular Health and Risk Management 2008:4(4) 766
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in type 2 diabetes, but due to the still unknown beneﬁ  t-risk 
ratio their use should currently be restricted to individual 
patients until long-term safety and efficacy data are 
reported.
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